197 related articles for article (PubMed ID: 31371410)
1. Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells.
Kumar H; Chattopadhyay S; Das N; Shree S; Patel D; Mohapatra J; Gurjar A; Kushwaha S; Singh AK; Dubey S; Lata K; Kushwaha R; Mohammed R; Dastidar KG; Yadav N; Vishwakarma AL; Gayen JR; Bandyopadhyay S; Chatterjee A; Jain MR; Tripathi AK; Trivedi AK; Chattopadhyay N; Ramachandran R; Sanyal S
Haematologica; 2020 Apr; 105(4):971-986. PubMed ID: 31371410
[TBL] [Abstract][Full Text] [Related]
2. Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells.
Wang J; Lu L; Kok CH; Saunders VA; Goyne JM; Dang P; Leclercq TM; Hughes TP; White DL
Haematologica; 2017 May; 102(5):843-853. PubMed ID: 28154092
[TBL] [Abstract][Full Text] [Related]
3. Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.
Cheng Y; Hao Y; Zhang A; Hu C; Jiang X; Wu Q; Xu X
Int J Mol Med; 2018 Jan; 41(1):455-463. PubMed ID: 29115375
[TBL] [Abstract][Full Text] [Related]
4. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
Chen CW; Lee YL; Liou JP; Liu YH; Liu CW; Chen TY; Huang HM
Apoptosis; 2016 Sep; 21(9):1008-18. PubMed ID: 27344662
[TBL] [Abstract][Full Text] [Related]
5. MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
Wong SM; Liu FH; Lee YL; Huang HM
PLoS One; 2016; 11(1):e0148093. PubMed ID: 26815740
[TBL] [Abstract][Full Text] [Related]
6. CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.
Guerra B; Martín-Rodríguez P; Díaz-Chico JC; McNaughton-Smith G; Jiménez-Alonso S; Hueso-Falcón I; Montero JC; Blanco R; León J; Rodríguez-González G; Estévez-Braun A; Pandiella A; Díaz-Chico BN; Fernández-Pérez L
Oncotarget; 2017 May; 8(18):29679-29698. PubMed ID: 27557509
[TBL] [Abstract][Full Text] [Related]
7. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
8. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
9. Novel AF1q/MLLT11 favorably affects imatinib resistance and cell survival in chronic myeloid leukemia.
Li W; Ji M; Lu F; Pang Y; Dong X; Zhang J; Li P; Ye J; Zang S; Ma D; Ji C
Cell Death Dis; 2018 Aug; 9(9):855. PubMed ID: 30154435
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.
Huang N; Huang Z; Gao M; Luo Z; Zhou F; Liu L; Xiao Q; Wang X; Feng W
J Exp Clin Cancer Res; 2018 Mar; 37(1):62. PubMed ID: 29554925
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
12. Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators.
Schoepf AM; Salcher S; Obexer P; Gust R
Eur J Med Chem; 2020 Jan; 185():111748. PubMed ID: 31648125
[TBL] [Abstract][Full Text] [Related]
13. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
Prost S; Relouzat F; Spentchian M; Ouzegdouh Y; Saliba J; Massonnet G; Beressi JP; Verhoeyen E; Raggueneau V; Maneglier B; Castaigne S; Chomienne C; Chrétien S; Rousselot P; Leboulch P
Nature; 2015 Sep; 525(7569):380-3. PubMed ID: 26331539
[TBL] [Abstract][Full Text] [Related]
14. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Carter BZ; Wang X; Shi X; Liu J
J Hematol Oncol; 2016 Nov; 9(1):129. PubMed ID: 27884201
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.
Rousselot P; Prost S; Guilhot J; Roy L; Etienne G; Legros L; Charbonnier A; Coiteux V; Cony-Makhoul P; Huguet F; Cayssials E; Cayuela JM; Relouzat F; Delord M; Bruzzoni-Giovanelli H; Morisset L; Mahon FX; Guilhot F; Leboulch P;
Cancer; 2017 May; 123(10):1791-1799. PubMed ID: 28026860
[TBL] [Abstract][Full Text] [Related]
16. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
17. Tackling resistance in chronic myeloid leukemia: Novel cell death modulators with improved efficacy.
Schoepf AM; Salcher S; Obexer P; Gust R
Eur J Med Chem; 2021 Apr; 216():113285. PubMed ID: 33662676
[TBL] [Abstract][Full Text] [Related]
18. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of
Deng Y; Li X; Feng J; Zhang X
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
[TBL] [Abstract][Full Text] [Related]
20. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells.
Ge Y; Yang B; Xu X; Dai Q; Chen Z; Cheng R
Leuk Lymphoma; 2015 Mar; 56(3):730-8. PubMed ID: 24884318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
